Press Releases

BOSTON and SYDNEY — 9 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients diagnosed with type 2 diabetes and obesity, is pleased to announce the first report from the Association of British Clinical Diabetologists (ABCD) Worldwide...

BOSTON and SYDNEY — 4 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce further positive results from the ongoing National Health Service (NHS) EndoBarrier Service in the U.K.,...

BOSTON and SYDNEY – 31 May 2018 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to confirm that, further to the Company’s announcement on 2 May 2018, it has completed the US$1,750,000 convertible note...

BOSTON and SYDNEY — 16 May 2018 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2018 Annual Meeting of Stockholders on 24 May 2018 at 6:00 pm United States Eastern Daylight Time, (which is 25 May 2018 at 8:00 am Australian Eastern Standard Time), at the offices of Mintz, Levin, Cohn,...

BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...

BOSTON and SYDNEY – 2 May 2018 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has received a binding commitment for a US$1,750,000 convertible note and warrant financing from Crystal Amber Fund Limited. The...

BOSTON and SYDNEY – 28 March 2018 – GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announced that it will release its 2017 Annual Report on Form 10K on or before 31 March EDT | 1 April AEST 2018. GI Dynamics...

BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has today successfully completed the second tranche of the Placement (as detailed further in the 23 January 2018 announcement).  The closing of...

BOSTON and SYDNEY — 28 February 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier®, held an adjourned Special Meeting on Tuesday, 27 February 2018 at 3:00pm Eastern Standard Time (being Wednesday, 28 February 2018 at 7:00am Australian Eastern Daylight...

BOSTON and SYDNEY — 07 February 2018— GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to confirm that, further to its announcement released on 23 January 2018, the attached proxy statement and notice of a special meeting of stockholders (Special...